Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01350947
Show Display Options
Rank Status Study
1 Completed A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: 5-Azacitidine

Indicates status has not been verified in more than two years